# Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct05569382` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05569382](<https://clinicaltrials.gov/study/NCT05569382>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05569382

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05569382. Randomized; triple masking; primary purpose treatment. Start 2022-08-10 (actual); primary completion 2027-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05569382, source copy `cardio:ctgov-nct05569382-2025-03-20`, retrieved 2026-10-31)
- Started: 2022-08-10 (actual) (ClinicalTrials.gov record NCT05569382, source copy `cardio:ctgov-nct05569382-2025-03-20`, retrieved 2026-10-31)
- Primary completion: 2027-04-01 (anticipated) (ClinicalTrials.gov record NCT05569382, source copy `cardio:ctgov-nct05569382-2025-03-20`, retrieved 2026-10-31)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT05569382, source copy `cardio:ctgov-nct05569382-2025-03-20`, retrieved 2026-10-31)
- Countries: Denmark (ClinicalTrials.gov record NCT05569382, source copy `cardio:ctgov-nct05569382-2025-03-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05569382-2025-03-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy
- Acronym: TEMPO II
- Condition: Non-obstructive Hypertrophic Cardiomyopathy
- Intervention (Drug): Verapamil
- Intervention (Drug): Bisoprolol
- Intervention (Drug): Placebo
- Lead sponsor: Morten Steen Kvistholm Jensen
- Lead sponsor class: OTHER
- Collaborator: Viborg Regional Hospital
- Collaborator class: OTHER
- Collaborator: Zealand University Hospital
- Collaborator class: OTHER
- Collaborator: Odense University Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry intervention name matches this record: Verapamil (`cardio:verapamil`)
- Registry intervention name matches this record: Bisoprolol (`cardio:bisoprolol`)
- Registry lists this organization as a collaborator: Zealand University Hospital (`cardio:org-zealand-university-hospital`)
- Registry lists this organization as a collaborator: Odense University Hospital (`cardio:org-odense-university-hospital`)

## Provenance

Content hash: 497f70edd5034f091cc911d3493c845f76e220b14f3f733965442c80e0d99fa7
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
